Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cyclophosphamide + Interferon alpha-2b + Pembrolizumab + SV-BR-1-GM|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 15||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Interferon alpha-2b||Intron A||Alfatronol|Alfatronol|interferon alpha-2b|Sch 30500|
|Pembrolizumab||Keytruda||MK-3475||Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 73||Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous squamous cell carcinoma, MSI-H or dMMR or TMB high advanced solid tumors, PD-L1 expressing NSCLC, gastric and GEJ adenocarcinoma, squamous esophageal carcinoma, cervical cancer, and triple-negative breast cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib in RCC, with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemotherapy for patients with esophageal or gastroesophageal carcinoma, and in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma (FDA.gov).|
|SV-BR-1-GM||Bria-IMT||SV-BR-1-GM is a vaccine comprised of breast cancer cells from the cell line, SV-BR-1, and granulocyte-macrophage colony-stimulating factor, which may lead to an immune response against breast cancer cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04418219||Phase Ib/II||Cyclophosphamide + Interferon alpha-2b + Pembrolizumab + SV-BR-1-GM||A Breast Cancer Vaccine (SV-BR-1-GM) in Combination With Pembrolizumab for the Treatment of Persistent, Recurrent, or Metastatic Breast Cancer||Withdrawn||USA||0|
|NCT03328026||Phase Ib/II||Cyclophosphamide + Interferon alpha-2b + Ipilimumab + SV-BR-1-GM Cyclophosphamide + Interferon alpha-2b + Pembrolizumab + SV-BR-1-GM||Rollover Study of SV-BR-1-GM in Combination With Ipilimumab or Pembrolizumab||Recruiting||USA||0|